Drug Pipeline

Acoramidis Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Phase 3

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-06-09	NCT07298044 A Study to Learn More About the Change in the Blood Levels of Transthyretin When…	date change Primary completion moved earlier: 2027-12-25 -> 2027-07-15
2026-06-09	NCT07298044 A Study to Learn More About the Change in the Blood Levels of Transthyretin When…	date change Completion moved earlier: 2027-12-25 -> 2027-07-15

Active Studies by Phase

Phase 4

Phase 3

Not specified

Active Trials

NCT ID	Title	Condition	Status
Phase 4
NCT07306949	Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association…	Transthyretin-type Cardiac Amyloidosis	Recruiting
NCT07298044	A Study to Learn More About the Change in the Blood Levels of Transthyretin When…	Transthyretin Amyloid Cardiomyopathy	Recruiting
Phase 3
NCT06563895	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in…	Amyloidosis	Recruiting
Not specified
NCT07235462	A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called…	Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Recruiting

Sponsors Running Acoramidis Trials

Bayer (2) Eidos Therapeutics, a BridgeBio company (1) Alexion Pharmaceuticals, Inc. (1)

Disease Areas

Amyloidosis (2) Heart Disease (1)

Get alerts when Acoramidis trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.